TY - JOUR
T1 - Drug-based optical agents
T2 - Infiltrating clinics at lower risk
AU - Scheuer, Werner
AU - Van Dam, Gooitzen M.
AU - Dobosz, Michael
AU - Schwaiger, Markus
AU - Ntziachristos, Vasilis
PY - 2012/5/16
Y1 - 2012/5/16
N2 - Fluorescent agents with specificity to cellular and subcellular moieties present promise for enhancing diagnostics and theranostics, yet challenges associated with regulatory approvals of experimental agents stifle the clinical translation. As a result, targeted fluorescent agents have remained predominantly as preclinical imaging tools. We discuss the potential of using optically labeled drugs to accelerate the clinical acceptance of optical and optoacoustic agents, in analogy to nuclear medicine approaches. This strategy, corroborated with microdosing studies, outlines a promising approach for overcoming bottlenecks and advancing photonic clinical imaging.
AB - Fluorescent agents with specificity to cellular and subcellular moieties present promise for enhancing diagnostics and theranostics, yet challenges associated with regulatory approvals of experimental agents stifle the clinical translation. As a result, targeted fluorescent agents have remained predominantly as preclinical imaging tools. We discuss the potential of using optically labeled drugs to accelerate the clinical acceptance of optical and optoacoustic agents, in analogy to nuclear medicine approaches. This strategy, corroborated with microdosing studies, outlines a promising approach for overcoming bottlenecks and advancing photonic clinical imaging.
UR - http://www.scopus.com/inward/record.url?scp=84861120243&partnerID=8YFLogxK
U2 - 10.1126/scitranslmed.3003572
DO - 10.1126/scitranslmed.3003572
M3 - Review article
C2 - 22593172
AN - SCOPUS:84861120243
SN - 1946-6234
VL - 4
JO - Science Translational Medicine
JF - Science Translational Medicine
IS - 134
M1 - 134ps11
ER -